

Tuberculosis profile: Liberia

Population 2019: 4.9 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	15 000 (9 800-22 000)	308 (199-440)
HIV-positive TB incidence	2 200 (1 400-3 100)	44 (29-63)
MDR/RR-TB incidence**	370 (160-670)	7.5 (3.2-14)
HIV-negative TB mortality	2 800 (1 600-4 200)	56 (33-85)
HIV-positive TB mortality	860 (550-1 200)	17 (11-25)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	2.5% (1.2-4.1)
Previously treated cases	0% (0-15)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	54% (38-84)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	25% (13-39)

TB case notifications, 2019

Total new and relapse	8 288
- % tested with rapid diagnostics at time of diagnosis	18%
- % with known HIV status	77%
- % pulmonary	64%
- % bacteriologically confirmed ^	67%
- % children aged 0-14 years	18%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	36%
- % men	46%
Total cases notified	8 323

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	922	14%
- on antiretroviral therapy	680	74%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	42%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	100%
Laboratory-confirmed cases - MDR/RR-TB ^^	91
Patients started on treatment - MDR/RR-TB ^^	83
Laboratory-confirmed cases - XDR-TB ^^	0
Patients started on treatment - XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	91

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	75%	7 703
Previously treated cases, excluding relapse, registered in 2018	75%	16
HIV-positive TB cases registered in 2018	66%	984
MDR/RR-TB cases started on second-line treatment in 2017	78%	55
XDR-TB cases started on second-line treatment in 2017		0

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment



Treatment success rate



Total budget



TB financing

National TB budget, 2020 (US\$ millions)	10
- Funding source, domestic	2.9%
- Funding source, international	18%
- unfunded	79%

* *Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*

** *MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin*

^ *Calculated for pulmonary cases only*

^^ *Includes cases with unknown previous TB treatment history*

^^^ *Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed*

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)